Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy efficacy in melanoma patients with brain metastases requiring steroids
2018-000875-34Phase 2Active
- Sponsor
- National Center for Cancer Immune Therapy
- Start
- Mar 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of nivolumab, ipilimumab and pembrolizumab in melanoma (2 arms), sponsored by National Center for Cancer Immune Therapy. Primary endpoint: 6-month progression-free survival rate. Started Mar 2018; status: active.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-000875-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000875-34.